MBC Advocate· @MBCadvocate · X·· 2026-04-21Score60
Reading
Next-generation ADCs: payload innovation
AVA6103 / pan-RAS ADC · Tricomplex pan-RAS as payload
Body
Best news ever! AVA6103 includes ER+ metastatic breast cancer! A major step forward!
Thank you to Team Avacta, patients, advocates, and investors for making this expansion possible. You’re the best! #AVCT #AACR26
Heat 101 · 88 likes · 2 replies · 11 reposts
Conference abstracts
5846matched by 代号 AVA6103
AVA6103 is a FAP-enabled pre|CISION®peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activityCurtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow
Read the abstract →Source: MBC Advocate · x.com